Previous research underlines the importance of the dose and timing of antiangiogenic treatment, aspects which significantly influence its toxicity [11,12], and vascular endothelial growth factor (VEGF) withdrawal leads to an increase in extracellular matrix (ECM) deposition in malignant tumors [13,14]. This evidence concerns the gene VEGFA and cancer.